The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS [Yahoo! Finance]
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Biogen (NASDAQ:BIIB) had its price target raised by analysts at BMO Capital Markets from $150.00 to $165.00. They now have a "market perform" rating on the stock.
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress [Yahoo! Finance]
Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.